Want to join the conversation?
$GILD 2Q15 Call: Pleased with the number of patients GILD is reaching with Sovaldi and Harvoni, which are now approved in 51 and 40 countries, respectively. Total HCV revenue was $4.9Bil. US HCV product revenue was $3.4Bil, of which Harvoni represented $2.8Bil. In 1H15, estimated 130K US hepatitis C patients started treatment on a Gilead product.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?